World Hepatitis Day–Bringing Hepatitis Care Closer To You
World Hepatitis Day is marked on 28 July each year to increase the awareness and understanding of viral hepatitis, which aims to call on the public to take the initiative to get vaccinated against hepatitis, to take the initiative to have a medical check-up to understand the health status of their liver, and to receive standardised antiviral treatment for patients with chronic viral hepatitis, in order to curb the threat of viral hepatitis to human health.
According to the World Health Organisation statistics, 325 million people worldwide are living with viral hepatitis B and C, and 1.4 million people lose their lives each year as a result, yet only 10% of people with hepatitis B and 19% of people with hepatitis C are aware of their hepatitis condition.
Studies have proven that long-term carriage of low-copy hepatitis B virus (HBV) has a certain chance of developing hepatocellular carcinoma (HCC) leading to death. Other studies have shown that HBV low-level viremia (LLV) predisposes the virus to drug-resistant mutations, and that persistent low viral infection may also lead to disease progression, increasing the risk of cirrhosis and liver cancer. Therefore, the Expert Opinion on Expanding Antiviral Therapy for Chronic Hepatitis B (2022) states: “The use of highly sensitive real-time quantitative PCR methods for HBV DNA testing in screened HBsAg-positive individuals and in patients with chronic hepatitis B who have already started antiviral therapy can help to detect patients with low viral load for early initiation of antiviral therapy or adjusting treatment regimens in a timely manner”.
TargetingOne HBV DNA assay uses microdroplet digital PCR for the absolute quantification of HBV DNA in serum or plasma samples, which is achieved by detecting the number of positive droplets and Poisson’s correction. In the assay, individual HBV DNA templates in the sample are wrapped in tens of thousands of microdroplets and amplified individually, which greatly reduces the effect of impurities in the sample and increases the sensitivity of the assay. When interpreting the results, the analyser counts the microdroplets one by one, allowing for accurate absolute quantification. The assay technique sets up an internal reference control to monitor the presence of PCR inhibitors in the sample to be tested by detecting whether the internal reference control is amplifying properly, thus avoiding PCR false negatives.
Product features:
High specificity: High resistance to interference, independent of amplification efficiency
High sensitivity: Minimum detection limit of 5 IU/mL
Absolute quantification: No standard curve required (avoiding operational errors and objective results)
Broad coverage: Detects 8 genotypes of HBV A, B, C, D, E, F, G and H
Effective anti-contamination: UNG enzyme + dUTP combined with the TargetingOne digital PCR anti-contamination system
Sample types: Serum, plasma, liver tissue biopsies
Ordering Information:
